Meta-analysis of Mendelian randomization studies

Tom Palmer, John Thompson and Martin Tobin

Department of Health Sciences,
University of Leicester, UK

ISCB 28,
1 August 2007

University *of* **Leicester**

Outline

1. Brief introduction to Mendelian randomization

2. Concepts in the meta-analysis model

3. Description of the example and the meta-analysis model

4. An extension to the meta-analysis model

5. Summary and discussion

Brief introduction to Mendelian randomization

- Dates back to [Katan, 1986], recent revival [Katan, 2004]

Brief introduction to Mendelian randomization

- Dates back to [Katan, 1986], recent revival [Katan, 2004]

  - Association between biological phenotype and a disease

# Brief introduction to Mendelian randomization

- Dates back to [Katan, 1986], recent revival [Katan, 2004]

  - Association between biological phenotype and a disease

    - Problems of confounding and reverse causation

Brief introduction to Mendelian randomization

- Dates back to [Katan, 1986], recent revival [Katan, 2004]

  - Association between biological phenotype and a disease

    - Problems of confounding and reverse causation

- Mendel's 2nd law: individual randomized to a genotype at conception

Brief introduction to Mendelian randomization

- Dates back to [Katan, 1986], recent revival [Katan, 2004]

  - Association between biological phenotype and a disease

    - Problems of confounding and reverse causation

- Mendel's 2nd law: individual randomized to a genotype at conception

 - Phenotype on pathway between gene and disease

θ: Gene-Disease log odds-ratio, δ: difference in mean phenotypes, η: Phenotype-Disease log odds-ratio

$$Genotype \xrightarrow{\quad \delta \quad} Phenotype \xrightarrow{\quad \eta \quad} Disease$$

θ: Gene-Disease log odds-ratio, δ: difference in mean phenotypes, η: Phenotype-Disease log odds-ratio

- Instrumental-variable (IV) methods for continuous outcome measures

$$\theta$$

$$Genotype \xrightarrow{\delta} Phenotype \xrightarrow{\eta} Disease$$

θ: Gene-Disease log odds-ratio, δ: difference in mean phenotypes, η: Phenotype-Disease log odds-ratio

- Instrumental-variable (IV) methods for continuous outcome measures

  - IV estimates using a binary disease outcome are approximations

$$\theta$$

$$\textit{Genotype} \xrightarrow{\ \delta\ } \textit{Phenotype} \xrightarrow{\ \eta\ } \textit{Disease}$$

θ: Gene-Disease log odds-ratio, δ: difference in mean phenotypes, η: Phenotype-Disease log odds-ratio

- Instrumental-variable (IV) methods for continuous outcome measures

  - IV estimates using a binary disease outcome are approximations

    - Ratio of coefficients approach,

$$\theta$$

Genotype $\xrightarrow{\delta}$ Phenotype $\xrightarrow{\eta}$ Disease

θ: Gene-Disease log odds-ratio, δ: difference in mean phenotypes, η: Phenotype-Disease log odds-ratio

- Instrumental-variable (IV) methods for continuous outcome measures

  - IV estimates using a binary disease outcome are approximations

    - Ratio of coefficients approach,

$$\eta_{[k]} \approx \frac{k\theta}{\delta}$$

Information from a case-control study

- A biallellic polymorphism (g,G); g: common allele, G: risk allele; 3 genotypes: gg, Gg, GG; ($j = 1, 2, 3$)

Information from a case-control study

- A biallellic polymorphism (g,G); g: common allele, G: risk allele; 3 genotypes: gg, Gg, GG; ($j = 1, 2, 3$)

  - $d = 0,1$: control/case,
  - y_{dj}: observed cases and controls,

Information from a case-control study

- A biallellic polymorphism (g,G); g: common allele, G: risk allele; 3 genotypes: gg, Gg, GG; ($j = 1, 2, 3$)

  - $d = 0,1$: control/case,

  y_{dj}: observed cases and controls,

|	gg	Gg	GG
Controls	y_{01}	y_{02}	y_{03}
Cases	y_{11}	y_{12}	y_{13}
log odds-ratios		θ_2	θ_3
Mean phenotype levels (controls)	μ_1	μ_2	μ_3
difference in mean phenotypes		δ_2	δ_3

Description of the example

- Mann et al. The Journal of Clinical Investigation, (2001); phenotype - bone mineral denisty (BMD), disease - osteoporotic fracture, gene - *COL1A1* codes for collagen

Description of the example

- Mann et al. The Journal of Clinical Investigation, (2001); phenotype - bone mineral denisty (BMD), disease - osteoporotic fracture, gene - *COL1A1* codes for collagen

Description of the meta-analysis model

- Meta-analysis model for Mendelian randomization studies for a single genotype comparison [Thompson et al., 2005].

Description of the meta-analysis model

- Meta-analysis model for Mendelian randomization studies for a single genotype comparison [Thompson et al., 2005].

    - Gg vs gg: Bigger sample size, smaller difference in disease risk; GG vs gg: Smaller sample size, bigger difference in disease risk

Description of the meta-analysis model

- Meta-analysis model for Mendelian randomization studies for a single genotype comparison [Thompson et al., 2005].

  - Gg vs gg: Bigger sample size, smaller difference in disease risk; GG vs gg: Smaller sample size, bigger difference in disease risk

  - Inference at the population level; marginal distribution: combine within and between study distributions

Description of the meta-analysis model

- Meta-analysis model for Mendelian randomization studies for a single genotype comparison [Thompson et al., 2005].

  - Gg vs gg: Bigger sample size, smaller difference in disease risk; GG vs gg: Smaller sample size, bigger difference in disease risk

  - Inference at the population level; marginal distribution: combine within and between study distributions

$$
\begin{bmatrix} \theta_{2i} \\ \delta_{2i} \\ \theta_{3i} \\ \delta_{3i} \end{bmatrix} \sim \text{MVN} \left(\begin{bmatrix} \eta\delta_2 \\ \delta_2 \\ \eta\delta_3 \\ \delta_3 \end{bmatrix}, \mathbf{V}_i + \mathbf{B} \right)
$$

- Results of the meta-analysis model

- Results of the meta-analysis model

Method of estimation	$OR_{pd,0.05}$	95% C.I.	
Gg vs gg	0.57	0.42	0.77
GG vs gg	0.40	0.28	0.57
Combined	0.50	0.39	0.62

- Results of the meta-analysis model

| Method of estimation	$OR_{pd,0.05}$	95% C.I.	
Gg vs gg	0.57	0.42	0.77
GG vs gg	0.40	0.28	0.57
Combined	0.50	0.39	0.62

- Given a 0.05 unit decrease in bone mineral density implies a typical patient is at twice the risk of osteoporotic fracture

- Results of the meta-analysis model

Method of estimation	$OR_{pd,0.05}$	95% C.I.	
Gg vs gg	0.57	0.42	0.77
GG vs gg	0.40	0.28	0.57
Combined	0.50	0.39	0.62

- Given a 0.05 unit decrease in bone mineral density implies a typical patient is at twice the risk of osteoporotic fracture

An extension to the meta-analysis model

- Genetic model-free approach - estimate λ - summary of mode of inheritance of the risk allele [Minelli et al., 2005]

An extension to the meta-analysis model

- Genetic model-free approach - estimate λ - summary of mode of inheritance of the risk allele [Minelli et al., 2005]

- Interpretation of λ; 0 - recessive, 0.5 - co-dominant, 1 - dominant

An extension to the meta-analysis model

- Genetic model-free approach - estimate λ - summary of mode of inheritance of the risk allele [Minelli et al., 2005]

- Interpretation of λ; 0 - recessive, 0.5 - co-dominant, 1 - dominant

  - Provided genotype is independent of the phenotype (and confounders) [Thompson et al., 2006]

$$\lambda = \frac{\theta_2}{\theta_3} = \frac{\delta_2}{\delta_3}$$

An extension to the meta-analysis model

- Genetic model-free approach - estimate λ - summary of mode of inheritance of the risk allele [Minelli et al., 2005]

- Interpretation of λ; 0 - recessive, 0.5 - co-dominant, 1 - dominant

  - Provided genotype is independent of the phenotype (and confounders) [Thompson et al., 2006]

$$\lambda = \frac{\theta_2}{\theta_3} = \frac{\delta_2}{\delta_3}$$

  - Extended meta-analysis model

An extension to the meta-analysis model

- Genetic model-free approach - estimate λ - summary of mode of inheritance of the risk allele [Minelli et al., 2005]

- Interpretation of λ; 0 - recessive, 0.5 - co-dominant, 1 - dominant

    - Provided genotype is independent of the phenotype (and confounders) [Thompson et al., 2006]

$$\lambda = \frac{\theta_2}{\theta_3} = \frac{\delta_2}{\delta_3}$$

    - Extended meta-analysis model

$$\begin{bmatrix} \theta_{2i} \\ \delta_{2i} \\ \theta_{3i} \\ \delta_{3i} \end{bmatrix} \sim \text{MVN} \left(\begin{bmatrix} \eta\lambda\delta \\ \lambda\delta \\ \eta\delta \\ \delta \end{bmatrix}, \mathbf{V}_i + \mathbf{\Sigma} \right)$$

- Estimation; maximum likelihood or Bayesian using Product Normal Formulation [Spiegelhalter, 1998]

- Estimation; maximum likelihood or Bayesian using Product Normal Formulation [Spiegelhalter, 1998]

$$\theta_{2i} \sim \mathsf{N}(\eta\lambda\delta, var(\theta_{2i})), \quad \delta_{2i} \sim \mathsf{N}(\lambda\delta, var(\delta_{2i}))$$
$$\theta_{3i} \sim \mathsf{N}(\eta\delta, var(\theta_{3i})), \quad \delta_{3i} \sim \mathsf{N}(\delta, var(\delta_{3i}))$$

- Estimation; maximum likelihood or Bayesian using Product Normal Formulation [Spiegelhalter, 1998]

$$\theta_{2i} \sim N(\eta\lambda\delta, var(\theta_{2i})), \quad \delta_{2i} \sim N(\lambda\delta, var(\delta_{2i}))$$
$$\theta_{3i} \sim N(\eta\delta, var(\theta_{3i})), \quad \delta_{3i} \sim N(\delta, var(\delta_{3i}))$$

- Prior distributions

$$\delta, \eta \sim N(0, 1 \times 10^6), \quad \lambda \sim Beta(0.5, 0.5)$$

- Estimation; maximum likelihood or Bayesian using Product Normal Formulation [Spiegelhalter, 1998]

$$\theta_{2i} \sim N(\eta\lambda\delta, var(\theta_{2i})), \quad \delta_{2i} \sim N(\lambda\delta, var(\delta_{2i}))$$
$$\theta_{3i} \sim N(\eta\delta, var(\theta_{3i})), \quad \delta_{3i} \sim N(\delta, var(\delta_{3i}))$$

- Prior distributions

$$\delta, \ \eta \sim N(0, 1 \times 10^6), \quad \lambda \sim Beta(0.5, 0.5)$$

- Results

- Estimation; maximum likelihood or Bayesian using Product Normal Formulation [Spiegelhalter, 1998]

$$\theta_{2i} \sim N(\eta\lambda\delta, var(\theta_{2i})), \quad \delta_{2i} \sim N(\lambda\delta, var(\delta_{2i}))$$
$$\theta_{3i} \sim N(\eta\delta, var(\theta_{3i})), \quad \delta_{3i} \sim N(\delta, var(\delta_{3i}))$$

- Prior distributions

$$\delta, \ \eta \sim N(0, 1 \times 10^6), \quad \lambda \sim Beta(0.5, 0.5)$$

- Results

Method of estimation	$OR_{pd,0.05}$	95% C.I./Cr.I.		λ	95% C.I./Cr.I.	
ML - MVN	0.42	0.28	0.61	0.33	0.19	0.47
Bayesian - PNF	0.46	0.32	0.61	0.30	0.17	0.45

Talk summary and discussion

- Random allocation of an individual's genotype allows use of instrumental variable theory

Talk summary and discussion

- Random allocation of an individual's genotype allows use of instrumental variable theory

  - Meta-analysis analysis of two genotype comparisons; extended to include the genetic model-free approach

Talk summary and discussion

- Random allocation of an individual's genotype allows use of instrumental variable theory

  - Meta-analysis analysis of two genotype comparisons; extended to include the genetic model-free approach

- Meta-analysis of genetic association studies using merged genotype comparisons [Salanti and Higgins, 2007]

Acknowledgements

- Student conference award

MRC | Medical Research Council

References

Katan, M. (1986).
Apolipoprotein e isoforms, serum cholesterol, and cancer.
Lancet, 327:507–508.

Katan, M. (2004).
Commentary: Mendelian randomization, 18 years on.
International Journal of Epidemiology, 33(1):10–11.

Minelli, C., Thompson, J., Abrams, K., Thakkinstian, A., and Attia, J. (2005).
The choice of a genetic model in the meta-analysis of molecular association studies.
International Journal of Epidemiology, 34:1319–1328.

Salanti, G. and Higgins, J. P. T. (2007).
Meta-analysis of genetic association studies under different inheritance models using data reported as merged genotypes.
Statistics in Medicine.
in press.

Spiegelhalter, D. (1998).
Bayesian graphical modelling: a case-study in monitoring health outcomes.
Applied Statistics, 47(1):115–133.

Thompson, J., Minelli, C., Abrams, K., Tobin, M., and Riley, R. (2005).
Meta-analysis of genetic studies using Mendelian randomization - a multivariate approach.
Statistics in Medicine, 24:2241–2254.

Thompson, J. R., Minelli, C., and Abrams, K. R. (2006).
Model-free meta-analysis of genetic association studies of continuous outcomes.
In *ISCB 27 Abstract Book*. ISCB.